BRCA1
BRCA2
EGFR
TP53
Triple negative breast cancer
Journal
International journal of molecular epidemiology and genetics
ISSN: 1948-1756
Titre abrégé: Int J Mol Epidemiol Genet
Pays: United States
ID NLM: 101525762
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
04
2020
accepted:
05
06
2020
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Triple negative breast cancer account for 10% to 20% of all newly diagnosed breast cancer cases, this subtype is well known for its lack of estrogen, progesterone and HER2 expression unlike the other subtypes of breast cancer that usually express at least one of the three. The absence of a specific biomarker for TNBC has made his treatment very challenging and his death rates very high compared to the other subtypes. Therefore, in morocco, many studies have been conducted in the hope of finding a specific biomarker for TNBC, but none of these studies has analyzed the EGFR protein expression and its gene molecular profile and correlated the EGFR analyses results with the genetic profile of other genes. In this study, we analyzed EGFR protein expression and the molecular profile of
Types de publication
Journal Article
Langues
eng
Pagination
16-25Informations de copyright
IJMEG Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Mod Pathol. 2016 May;29(5):476-88
pubmed: 26939876
Am J Cancer Res. 2016 Aug 01;6(8):1609-23
pubmed: 27648353
Fam Cancer. 2004;3(1):15-20
pubmed: 15131401
JAMA. 2007 Dec 26;298(24):2869-76
pubmed: 18159056
Cancer Genet Cytogenet. 2010 Dec;203(2):222-9
pubmed: 21156237
Breast Cancer Res Treat. 2013 Jan;137(1):119-25
pubmed: 23192404
Breast Cancer. 2014 Jan;21(1):66-74
pubmed: 22481575
Gynecol Oncol. 2012 Jun;125(3):687-92
pubmed: 22425665
BMC Cancer. 2018 Sep 18;18(1):900
pubmed: 30227836
Clin Cancer Res. 2012 Mar 1;18(5):1341-51
pubmed: 22261811
Cancer. 2012 Jun 1;118(11):2787-95
pubmed: 22614657
Oncotarget. 2016 Oct 18;7(42):67686-67698
pubmed: 27611952
Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
Histopathology. 2011 Aug;59(2):264-73
pubmed: 21884205
Patholog Res Int. 2014;2014:141864
pubmed: 25400978
J Breast Cancer. 2016 Sep;19(3):223-230
pubmed: 27721871
Cancer. 2015 Jan 1;121(1):8-16
pubmed: 25043972
J Pathol. 2006 Aug;209(4):445-53
pubmed: 16739104
Histol Histopathol. 2012 Jun;27(6):785-92
pubmed: 22473698
PLoS One. 2013 Oct 30;8(10):e79014
pubmed: 24205362
Carcinogenesis. 2012 Nov;33(11):2007-17
pubmed: 22822097
Int J Cancer. 2013 Mar 1;132(5):1227-31
pubmed: 22886769
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
Cancer Res. 2009 Jan 15;69(2):663-71
pubmed: 19147582
Mol Genet Metab. 2000 Feb;69(2):130-6
pubmed: 10720440
Br J Cancer. 2014 Feb 18;110(4):1045-52
pubmed: 24423920
Cancer Res. 1992 Jul 15;52(14):3918-23
pubmed: 1617667
J Clin Oncol. 2012 May 20;30(15):1879-87
pubmed: 22454417
Cancer. 2007 Aug 15;110(4):876-84
pubmed: 17620276
Breast Cancer Res Treat. 2012 Jul;134(2):561-7
pubmed: 22610646
Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75
pubmed: 21342044
Onco Targets Ther. 2019 Sep 20;12:7749-7756
pubmed: 31571924
Asian Pac J Cancer Prev. 2013;14(10):6013-7
pubmed: 24289617
Breast Cancer Res. 2011;13(6):R133
pubmed: 22192147
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Dis Markers. 2015;2015:194293
pubmed: 25814778
FEBS Lett. 2003 Apr 24;541(1-3):149-54
pubmed: 12706836
J Breast Cancer. 2017 Jun;20(2):150-159
pubmed: 28690651
Trends Pharmacol Sci. 2015 Dec;36(12):822-846
pubmed: 26538316
J Clin Oncol. 2015 Feb 1;33(4):304-11
pubmed: 25452441
Cancer Genomics Proteomics. 2017 May-Jun;14(3):181-195
pubmed: 28446533
Growth Factors. 2008 Oct;26(5):263-74
pubmed: 18800267
Oncotarget. 2014 Oct 30;5(20):9952-65
pubmed: 25296970
Gene. 2016 Jun 10;584(1):26-30
pubmed: 26956035
BMC Cancer. 2008 Oct 25;8:309
pubmed: 18950515
Breast Cancer Res. 2011 Apr 01;13(2):R35
pubmed: 21457545
Mod Pathol. 2014 Sep;27(9):1212-22
pubmed: 24406864
Oncol Lett. 2014 Jan;7(1):278-284
pubmed: 24348864